Inclusion Criteria:

- Participant must sign an informed consent document indicating they understand the
purpose of and procedures required for the study, including DNA analysis, and are
willing to participate in the study

- Must agree to use an adequate contraception method as deemed appropriate by the
investigator (eg, vasectomy, double-barrier, partner using effective contraception)
during the study and for 3 months after receiving the study drug

- Must agree to not donate sperm during the study and for 3 months after receiving the
study drug

- Blood pressure (after the participant is supine for 5 minutes) between 90 and 140
mmHg systolic, inclusive, and no higher than 90 mmHg diastolic

- Non-smoker (not smoked for 6 months prior to screening)

Exclusion Criteria:

- History of or current clinically significant medical illness including cardiac
arrhythmias or other cardiac disease, hematologic disease, coagulation disorders,
lipid abnormalities, significant pulmonary disease, including bronchospastic
respiratory disease, diabetes mellitus, renal or hepatic insufficiency, thyroid
disease, neurologic or psychiatric disease

- Clinically significant abnormal values for hematology, coagulation and platelet
function, clinical chemistry or urinalysis at screening as deemed appropriate by the
investigator

- Clinically significant abnormal physical examination, vital signs or 12 lead
electrocardiogram (ECG) at screening as deemed appropriate by the investigator

- History of clinically significant allergies, especially known hypersensitivity or
intolerance to β-lactam antibiotics or sulfonamides

- Known allergy to heparin or history of heparin induced thrombocytopenia